About HAVAH Therapeutics

About company

Originally founded in Australia in 2006, Palo Alto-based HAVAH Therapeutics Inc. is a clinical-stage pharmaceutical company specialising in the development of novel therapeutics for the prevention of breast cancer. Breast cancer prevention is a critical, unmet global need. HAVAH's lead product candidate, T+Ai, is a proprietary breakthrough breast cancer prevention combination therapy - reducing a woman’s risk of breast cancer whilst improving their sense of wellbeing.